戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 usly irradiated bone metastases benefit from reirradiation.
2 isting organ dysfunction, for survival after reirradiation.
3 t prognostic factors for patients undergoing reirradiation.
4 for management and reviews recent results of reirradiation.
5 atients who underwent salvage surgery before reirradiation.
6                                   Concurrent reirradiation and chemotherapy is an alternative strateg
7 ces within the metastatic disease continuum, reirradiation, and emerging types of radiation therapy.
8 iation, recurrent tumor stage, tumor bulk at reirradiation, and reirradiation dose.
9             Data are accumulating to support reirradiation as a potentially curative approach for pat
10  electronic records of patients treated with reirradiation between January 1998 and 2008 were reviewe
11 gery before H-SRT, time to first recurrence, reirradiation dose, inclusion of chemotherapy with H-SRT
12 umor stage, tumor bulk at reirradiation, and reirradiation dose.
13                                              Reirradiation is a treatment option, although it is asso
14 necrosis of healthy brain tissue; therefore, reirradiation is usually not offered to patients with re
15 with both comorbidity and organ dysfunction, reirradiation largely serves as a palliative therapy.
16 Intensity-modulated radiation therapy (IMRT) reirradiation of nonmetastatic recurrent or second prima
17                       Patients responding to reirradiation of painful bone metastases experience supe
18 ared with previous reports with photon-based reirradiation, patients are living longer with aggressiv
19                        Use of proton therapy reirradiation (PT-ReRT) for head and neck cancer is incr
20 e/thrombosis/death) were comparable to prior reirradiation reports.
21                                        Focal reirradiation represents an option for select patients w
22 ticenter nonrandomized phase 2 trial of IMRT reirradiation therapy and nivolumab suggested a promisin
23                                       Before reirradiation, visual acuity ranged from 20/80 to counti
24  probability of death within 24 months after reirradiation was developed (concordance index = 0.75).
25                                              Reirradiation was only temporizing for SJMB03 patients.
26                                              Reirradiation with EBRT for locally recurrent PCa after
27 ts from a prospective study on focal salvage reirradiation with external-beam radiation therapy with